TSVT — 2Seventy Bio Share News
0.000.00%
Last trade - 00:00- $265.62m
- $95.24m
- $37.86m
2Seventy Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: 2Seventy Bio Q4 Basic EPS USD -0.37
2Seventy Bio Inc expected to post a loss of 26 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Elevance, Backblaze, Disney
U.S. STOCKS ON THE MOVE-BankUnited, Hesai Group, Sezzle
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Primo Brands, Exxon, FB Financial
U.S. STOCKS ON THE MOVE-Tesla, Venture Global, Delta Air Lines
Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million
2seventy bio rises on Bristol Myers buyout deal
Brief: 2Seventy Bio Enters Into Agreement To Be Acquired By Bristol Myers Squibb at $5.00 Per Share
2Seventy Bio Inc reports results for the quarter ended September 30 - Earnings Summary
2Seventy Bio Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: 2Seventy Bio - Abecma (Idecabtagene Vicleucel, Or Ide-Cel) Generated About $77 Million In U.S. Revenue During Q3 2024
U.S. STOCKS ON THE MOVE-SLM Corp, Amgen Inc, Cintas Corp
U.S. STOCKS ON THE MOVE-DoorDash, KB Home, Tyson Foods
U.S. STOCKS ON THE MOVE-DoorDash, KB Home, Tyson Foods
2seventy bio falls after co stops enrolling patients for blood cancer therapy trial
2seventy Bio stops enrolling patients in blood cancer therapy study (updated)